Skip to main content

Table 1 Physician Sociodemographics and Clinical Experience

From: Attitudes of European physicians towards the use of long-acting injectable antipsychotics

Characteristic

Physicians, n (%)

(N = 136a)

Clinician status

 Resident/Trainee

19 (14.0)

 Consultant

115 (84.6)

 Other/Missing

2 (1.5)

Country

 UK

43 (31.6)

 Germany

35 (25.7)

 Austria

2 (1.5)

 France

23 (16.9)

 Spain

30 (22.1)

 Sweden

3 (2.2)

Setting

 NHS only

37 (27.2)

 Private practice only

24 (17.6)

 Both NHS and private practice

6 (4.4)

 University clinic

44 (32.4)

 Other clinic

25 (18.4)

In your opinion, does your country have a history of large scale use of first generation LAI prescriptions (> 20% of all antipsychotic prescriptions)?

 Yes, and this is still the case

30 (22.1)

 Yes, but this number has dropped

80 (58.8)

 Not historically, but this is now the case

8 (5.9)

 No, this was never the case

18 (13.2)

Has your rate of prescribing LAI antipsychotics for schizophrenia changed over the last 5 years?

 Marked decrease

2 (1.5)

 Slight decrease

16 (11.8)

 Unchanged

37 (27.2)

 Slight increase

55 (40.4)

 Marked increase

26 (19.1)

How would you rate your level of clinical experience with the use of antipsychotics LAIs for schizophrenia?

 No experience

1 (0.7)

 Minimal experience

2 (1.5)

 Somewhat experienced

28 (20.6)

 Very experienced

105 (77.2)

  1. a177/234 solicited physicians returned a questionnaire. 136 were completed in full, 35 were excluded because they were incomplete, 5 were excluded because the physician answered no to the section “Willingness to voluntarily complete the questionnaire”, and 1 was excluded because the answer to the section “Willingness to voluntarily complete the questionnaire” was missing. LAI, long-acting injectable; NHS, National Health Service